Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Indomethacin Use for Mild & Moderate hospitalised Covid-19 patients: An open label randomized clinical trial

Rajan Ravichandran, Surapaneni Krishna Mohan, Suresh Kumar Sukumaran, Devakumar Kamaraj, Sumetha Suga Daivasuga, Samson Oliver Abraham Samuel Ravi, Sivakumar Vijayaraghavalu, Ramarathnam Krishna Kumar
doi: https://doi.org/10.1101/2021.07.24.21261007
Rajan Ravichandran
1Department of Nephrology, MIOT International, Chennai 600089, India and Adjunct Faculty, Indian Institute of Technology Madras (IITM), Chennai 600036, Tamil Nadu (TN), India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Surapaneni Krishna Mohan
2Departments of Biochemistry, Molecular Virology & Research, Panimalar Medical College Hospital & Research Institute, Chennai 600123, TN, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Suresh Kumar Sukumaran
3Department of General Medicine, Panimalar Medical College Hospital & Research Institute, Chennai 600123, TN, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Devakumar Kamaraj
4Departments of Pharmacology & Research, Panimalar Medical College Hospital & Research Institute, Chennai 600123, TN, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sumetha Suga Daivasuga
5Departments of Microbiology & Molecular Virology, Panimalar Medical College Hospital & Research Institute, Chennai 600123, TN, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Samson Oliver Abraham Samuel Ravi
6Molbio Diagnostics Private Limited, Verna Industrial Estate, Verna, Goa - 403 722, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Sivakumar Vijayaraghavalu
7Narayana Translational Research and Incubation Center, Narayana Medical College, Nellore 524003, Andhra Pradesh, India and Adjunct Faculty, IITM, Chennai 600036, TN, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Ramarathnam Krishna Kumar
8Department of Engineering Design, IITM, Chennai 600036, TN, India
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: rkkumar@iitm.ac.in
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Supplementary material
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Introduction Indomethacin, a non-steroidal anti-inflammatory drug (NSAID), has been presented as a broad-spectrum antiviral agent. This randomised clinical trial in a hospital setting evaluated the efficacy and safety of this drug in RT-PCR-positive coronavirus disease 2019 (COVID-19) patients.

Materials & Methods A total of 210 RT-PCR-positive COVID-19 patients, who provided consent were allotted, to control or case arm, based on block randomisation. The control arm received standard of care comprising paracetamol, ivermectin, and other adjuvant therapies. The patients in the case arm received indomethacin instead of paracetamol, with other medications retained. The primary endpoint was the development of hypoxia/desaturation with SpO2 ≤ 93, while time to become afebrile and time for cough and myalgia resolution were the secondary endpoints.

Results The results of 210 patients were available, with 103 and 107 patients in the indomethacin and paracetamol arms, respectively. We monitored patient profiles along with everyday clinical parameters. Blood chemistry at the time of admission and discharge was assessed.

As no one in either of the arms required high-flow oxygen, desaturation with SpO2 level of 93 and below was an important goal. In the indomethacin group, none of the 103 patients developed desaturation. On the other hand, 20 of the 107 patients in the paracetamol arm developed desaturation. Patients who received indomethacin also experienced more rapid symptomatic relief than those in the paracetamol arm, with most symptoms disappearing in half the time. 56 patients out of 107 in the paracetamol arm had fever on the seventh day, while no patient in the indomethacin group had fever. Neither arm reported any adverse event. The fourteenth-day follow-up revealed that the paracetamol arm patients had faced several discomforts, including myalgia, joint pain, and tiredness; indomethacin arm patients mostly complained only of tiredness.

Conclusion Indomethacin is a safe and effective drug for treating patients with mild and moderate covid-19.

Competing Interest Statement

The authors have declared no competing interest.

Clinical Trial

CTRI Registration No CTRI/2021/05/033544

Funding Statement

Funding: Funding for this study was provided by Mr. Kris Gopalakrishnan, Alumnus of the Indian Institute of Technology Madras. He is also the Chairman of Axilor Ventures

Author Declarations

I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.

Yes

The details of the IRB/oversight body that provided approval or exemption for the research described are given below:

The approval for the study was given by the ethics committee of the Panimalar Medical College. The document no : PMCH&RI/IHEC/2021/051

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Footnotes

  • Conflict of Interest We have read and understood the policy on declaration of interests and declare that we have no competing interests.

  • The paper has been rewritten. Complete data has been provided.

Data Availability

All data are available as supplementary file

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-ND 4.0 International license.
Back to top
PreviousNext
Posted October 03, 2021.
Download PDF

Supplementary Material

Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Indomethacin Use for Mild & Moderate hospitalised Covid-19 patients: An open label randomized clinical trial
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Indomethacin Use for Mild & Moderate hospitalised Covid-19 patients: An open label randomized clinical trial
Rajan Ravichandran, Surapaneni Krishna Mohan, Suresh Kumar Sukumaran, Devakumar Kamaraj, Sumetha Suga Daivasuga, Samson Oliver Abraham Samuel Ravi, Sivakumar Vijayaraghavalu, Ramarathnam Krishna Kumar
medRxiv 2021.07.24.21261007; doi: https://doi.org/10.1101/2021.07.24.21261007
Reddit logo Twitter logo Facebook logo LinkedIn logo Mendeley logo
Citation Tools
Indomethacin Use for Mild & Moderate hospitalised Covid-19 patients: An open label randomized clinical trial
Rajan Ravichandran, Surapaneni Krishna Mohan, Suresh Kumar Sukumaran, Devakumar Kamaraj, Sumetha Suga Daivasuga, Samson Oliver Abraham Samuel Ravi, Sivakumar Vijayaraghavalu, Ramarathnam Krishna Kumar
medRxiv 2021.07.24.21261007; doi: https://doi.org/10.1101/2021.07.24.21261007

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Infectious Diseases (except HIV/AIDS)
Subject Areas
All Articles
  • Addiction Medicine (227)
  • Allergy and Immunology (500)
  • Anesthesia (110)
  • Cardiovascular Medicine (1226)
  • Dentistry and Oral Medicine (205)
  • Dermatology (147)
  • Emergency Medicine (282)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (528)
  • Epidemiology (9998)
  • Forensic Medicine (5)
  • Gastroenterology (497)
  • Genetic and Genomic Medicine (2441)
  • Geriatric Medicine (236)
  • Health Economics (479)
  • Health Informatics (1634)
  • Health Policy (750)
  • Health Systems and Quality Improvement (633)
  • Hematology (247)
  • HIV/AIDS (530)
  • Infectious Diseases (except HIV/AIDS) (11854)
  • Intensive Care and Critical Care Medicine (625)
  • Medical Education (251)
  • Medical Ethics (74)
  • Nephrology (267)
  • Neurology (2271)
  • Nursing (139)
  • Nutrition (349)
  • Obstetrics and Gynecology (451)
  • Occupational and Environmental Health (532)
  • Oncology (1244)
  • Ophthalmology (375)
  • Orthopedics (133)
  • Otolaryngology (226)
  • Pain Medicine (154)
  • Palliative Medicine (50)
  • Pathology (324)
  • Pediatrics (728)
  • Pharmacology and Therapeutics (311)
  • Primary Care Research (281)
  • Psychiatry and Clinical Psychology (2279)
  • Public and Global Health (4822)
  • Radiology and Imaging (833)
  • Rehabilitation Medicine and Physical Therapy (488)
  • Respiratory Medicine (650)
  • Rheumatology (283)
  • Sexual and Reproductive Health (237)
  • Sports Medicine (224)
  • Surgery (266)
  • Toxicology (44)
  • Transplantation (124)
  • Urology (99)